Cargando…
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117078/ https://www.ncbi.nlm.nih.gov/pubmed/36877058 http://dx.doi.org/10.1128/msphere.00651-22 |
_version_ | 1785028554116825088 |
---|---|
author | Mojica, María Fernanda De La Cadena, Elsa García-Betancur, Juan Carlos Porras, Jessica Novoa-Caicedo, Isabella Páez-Zamora, Laura Pallares, Christian Appel, Tobias Manuel Radice, Marcela A. Castañeda-Méndez, Paulo Gales, Ana C. Munita, José M. Villegas, María Virginia |
author_facet | Mojica, María Fernanda De La Cadena, Elsa García-Betancur, Juan Carlos Porras, Jessica Novoa-Caicedo, Isabella Páez-Zamora, Laura Pallares, Christian Appel, Tobias Manuel Radice, Marcela A. Castañeda-Méndez, Paulo Gales, Ana C. Munita, José M. Villegas, María Virginia |
author_sort | Mojica, María Fernanda |
collection | PubMed |
description | Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (bla(OXA-50-like)), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms. |
format | Online Article Text |
id | pubmed-10117078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-101170782023-04-21 Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals Mojica, María Fernanda De La Cadena, Elsa García-Betancur, Juan Carlos Porras, Jessica Novoa-Caicedo, Isabella Páez-Zamora, Laura Pallares, Christian Appel, Tobias Manuel Radice, Marcela A. Castañeda-Méndez, Paulo Gales, Ana C. Munita, José M. Villegas, María Virginia mSphere Research Article Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (bla(OXA-50-like)), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms. American Society for Microbiology 2023-03-06 /pmc/articles/PMC10117078/ /pubmed/36877058 http://dx.doi.org/10.1128/msphere.00651-22 Text en Copyright © 2023 Mojica et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Mojica, María Fernanda De La Cadena, Elsa García-Betancur, Juan Carlos Porras, Jessica Novoa-Caicedo, Isabella Páez-Zamora, Laura Pallares, Christian Appel, Tobias Manuel Radice, Marcela A. Castañeda-Méndez, Paulo Gales, Ana C. Munita, José M. Villegas, María Virginia Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title | Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title_full | Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title_fullStr | Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title_full_unstemmed | Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title_short | Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals |
title_sort | molecular mechanisms of resistance to ceftazidime/avibactam in clinical isolates of enterobacterales and pseudomonas aeruginosa in latin american hospitals |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117078/ https://www.ncbi.nlm.nih.gov/pubmed/36877058 http://dx.doi.org/10.1128/msphere.00651-22 |
work_keys_str_mv | AT mojicamariafernanda molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT delacadenaelsa molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT garciabetancurjuancarlos molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT porrasjessica molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT novoacaicedoisabella molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT paezzamoralaura molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT pallareschristian molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT appeltobiasmanuel molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT radicemarcelaa molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT castanedamendezpaulo molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT galesanac molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT munitajosem molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals AT villegasmariavirginia molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals |